Impact of smoking on pemphigus

Authors

  • Mahin Valikhani MD,

    1. From the Pemphigus Research Center, Razi Hospital, Department of Dermatology, School of Medicine and Medical Sciences, University of Tehran, Tehran, Iran
    Search for more papers by this author
  • Suzan Kavusi MD,

    1. From the Pemphigus Research Center, Razi Hospital, Department of Dermatology, School of Medicine and Medical Sciences, University of Tehran, Tehran, Iran
    Search for more papers by this author
  • Cheyda Chams-Davatchi MD,

    1. From the Pemphigus Research Center, Razi Hospital, Department of Dermatology, School of Medicine and Medical Sciences, University of Tehran, Tehran, Iran
    Search for more papers by this author
  • Zahra Hallaji MD,

    1. From the Pemphigus Research Center, Razi Hospital, Department of Dermatology, School of Medicine and Medical Sciences, University of Tehran, Tehran, Iran
    Search for more papers by this author
  • Nafiseh Esmaili MD,

    1. From the Pemphigus Research Center, Razi Hospital, Department of Dermatology, School of Medicine and Medical Sciences, University of Tehran, Tehran, Iran
    Search for more papers by this author
  • Narges Ghandi MD,

    1. From the Pemphigus Research Center, Razi Hospital, Department of Dermatology, School of Medicine and Medical Sciences, University of Tehran, Tehran, Iran
    Search for more papers by this author
  • Farzaneh Farahani MD,

    1. From the Pemphigus Research Center, Razi Hospital, Department of Dermatology, School of Medicine and Medical Sciences, University of Tehran, Tehran, Iran
    Search for more papers by this author
  • Vahide Lajevardi MD

    1. From the Pemphigus Research Center, Razi Hospital, Department of Dermatology, School of Medicine and Medical Sciences, University of Tehran, Tehran, Iran
    Search for more papers by this author

Suzan Kavusi, MD 25/1-Noor Alley Africa Blvd Tehran 1917733551 Iran E-mail: sukavusi@yahoo.com

Abstract

Background  A positive history of smoking is less common in patients with pemphigus than in healthy subjects. The aim of this case–control study was to compare the remission rate and clinical locations involved in smokers and nonsmokers with pemphigus vulgaris.

Methods  Seventy patients with pemphigus vulgaris, treated with a uniform protocol, were enrolled. The sites of involvement, average time needed for disease control, and number of relapses were compared in smokers and nonsmokers. At the end of the first and second years of treatment, the rate of remission was compared in the two groups.

Results  Ten of the patients were current cigarette smokers, but the other 60 (85.7%) had no history of smoking. There was no difference in the rate of cutaneous or mucosal involvement between smokers and nonsmokers. The predominant subtype was the mucocutaneous type in both groups. Smokers with pemphigus vulgaris achieved partial remission more frequently than nonsmokers at the end of the first year of treatment. The number of patients in remission at the end of the second year of therapy was significantly higher for smokers with pemphigus than for nonsmokers. The main reason for disease activity in both groups was recurrence.

Conclusions  Cigarette smoking may not affect the rate of cutaneous or mucosal involvement in pemphigus; however, the data indicate that remission may be achieved sooner in pemphigus patients who smoke.

Ancillary